Moderna Historical Financial Ratios
MRNA Stock | USD 43.06 0.33 0.76% |
Moderna is lately reporting on over 104 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 45.17 will help investors to properly organize and evaluate Moderna financial condition quickly.
Moderna |
About Moderna Financial Ratios Analysis
ModernaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Moderna investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Moderna financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Moderna history.
Moderna Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Moderna stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Moderna sales, a figure that is much harder to manipulate than other Moderna multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Moderna dividend as a percentage of Moderna stock price. Moderna dividend yield is a measure of Moderna stock productivity, which can be interpreted as interest rate earned on an Moderna investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Moderna's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.At present, Moderna's Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 2.20, whereas Price To Sales Ratio is forecasted to decline to 5.27.
2023 | 2024 (projected) | Dividend Yield | 1.91E-4 | 1.21E-4 | Price To Sales Ratio | 5.55 | 5.27 |
Moderna fundamentals Correlations
Click cells to compare fundamentals
Moderna Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Moderna fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 134.7 | 145.13 | 5.77 | 3.67 | 5.55 | 5.27 | |
Ptb Ratio | 5.51 | 15.56 | 7.24 | 3.7 | 2.74 | 2.61 | |
Days Sales Outstanding | 40.8 | 1.9K | 65.34 | 26.24 | 47.54 | 45.17 | |
Book Value Per Share | 3.55 | 6.72 | 35.1 | 48.54 | 36.27 | 38.08 | |
Free Cash Flow Yield | (0.0758) | 0.0492 | 0.13 | 0.0647 | (0.1) | (0.0957) | |
Operating Cash Flow Per Share | (1.39) | 5.32 | 33.8 | 12.64 | (8.16) | (7.75) | |
Stock Based Compensation To Revenue | 1.69 | 0.34 | 0.008006 | 0.0117 | 0.0445 | 0.0423 | |
Capex To Depreciation | 1.02 | 2.16 | 1.22 | 1.15 | 1.14 | 2.2 | |
Pb Ratio | 5.51 | 15.56 | 7.24 | 3.7 | 2.74 | 2.61 | |
Ev To Sales | 129.79 | 135.57 | 5.38 | 3.51 | 5.3 | 5.04 | |
Free Cash Flow Per Share | (1.48) | 5.14 | 33.09 | 11.63 | (10.01) | (9.51) | |
Roic | (0.46) | (0.3) | 0.81 | 0.43 | (0.37) | (0.35) | |
Net Income Per Share | (1.55) | (1.96) | 30.28 | 21.22 | (12.34) | (11.72) | |
Payables Turnover | 4.38 | 0.44 | 8.67 | 11.12 | 9.03 | 4.97 | |
Sales General And Administrative To Revenue | 0.37 | 0.77 | 2.28 | 0.0525 | 0.2 | 0.19 | |
Research And Ddevelopement To Revenue | 10.33 | 4.99 | 0.11 | 0.17 | 0.71 | 0.67 | |
Capex To Revenue | 0.66 | 0.25 | 0.016 | 0.0208 | 0.1 | 0.0981 | |
Cash Per Share | 3.33 | 12.08 | 26.62 | 25.13 | 22.52 | 11.33 | |
Pocfratio | (14.1) | 19.65 | 7.51 | 14.21 | (12.18) | (11.57) | |
Interest Coverage | (82.53) | (77.19) | 738.67 | 324.83 | (111.55) | (117.13) | |
Capex To Operating Cash Flow | (0.0687) | 0.0333 | 0.0209 | 0.0803 | (0.23) | (0.22) | |
Pfcf Ratio | (13.19) | 20.33 | 7.68 | 15.45 | (9.93) | (9.44) | |
Days Payables Outstanding | 83.42 | 828.19 | 42.12 | 32.82 | 40.44 | 38.42 | |
Income Quality | 0.89 | (2.71) | 1.12 | 0.6 | 0.66 | 0.69 | |
Roe | (0.44) | (0.29) | 0.86 | 0.44 | (0.34) | (0.32) | |
Ev To Operating Cash Flow | (13.58) | 18.36 | 7.01 | 13.56 | (11.65) | (11.07) | |
Pe Ratio | (12.59) | (53.33) | 8.39 | 8.46 | (8.06) | (8.46) | |
Return On Tangible Assets | (0.2) | (0.32) | (0.1) | 0.49 | 0.32 | (0.26) | |
Ev To Free Cash Flow | (12.71) | 18.99 | 7.16 | 14.75 | (9.5) | (9.02) | |
Earnings Yield | (0.0366) | (0.31) | (0.0794) | (0.0188) | 0.12 | (0.12) | |
Net Debt To E B I T D A | 0.46 | 3.58 | (0.51) | (0.33) | 0.51 | 0.86 | |
Current Ratio | 7.89 | 1.43 | 1.76 | 2.73 | 3.42 | 4.82 | |
Tangible Book Value Per Share | 3.55 | 6.72 | 35.1 | 48.54 | 36.02 | 37.82 | |
Receivables Turnover | 8.95 | 0.19 | 5.59 | 13.91 | 7.68 | 5.56 | |
Graham Number | 11.14 | 17.21 | 154.63 | 152.24 | 100.35 | 105.37 | |
Shareholders Equity Per Share | 3.55 | 6.72 | 35.1 | 48.54 | 36.27 | 38.08 | |
Capex Per Share | 0.0954 | 0.18 | 0.7 | 1.02 | 1.85 | 1.94 | |
Graham Net Net | 2.09 | 2.39 | 8.2 | 11.88 | 12.57 | 13.2 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (5.81) | Revenue Per Share 13.275 | Quarterly Revenue Growth 0.017 | Return On Assets (0.1) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.